Mezzion Pharma: Small Revenue, Continued Losses and a Market Value Far Above the Model Estimate

Thesis

The data supports a picture of a loss-making biotech whose market value rests on expectations rather than reported earnings. Revenue has fallen from ₩31.7T-scale... correction: from ₩31.7B in 2023 to ₩7.9B in 2025, and operating losses have continued every year from 2021 to H1 2026. The share price is up 14.8% over 3 months but down 12.8% over 1 month and 8.4% over 1 year, and it sits well below its 52-week high of ₩179,900 (low ₩45,850). The data does not show the drivers of the share price moves, as no news headlines, investor flow, foreign ownership or short balance data are available. Two 5%+ holding reports in October 2026 and a series of insider shareholding reports are visible, but their content is not in the data.

Business overview

Mezzion Pharma is a KOSDAQ-listed Biotech & Pharma company, founded on 2002-09-25 and listed on 2012-01-20, with 29,963,337 listed shares. The CEO is listed as 박동현. Market capitalization is about ₩1.88T and enterprise value about ₩1.84T. Annual revenue was ₩26.7B in 2021, ₩30.7B in 2022, ₩31.7B in 2023, ₩8.6B in 2024 and ₩7.9B in 2025. The data does not describe products or pipeline.

Financial analysis

All figures come from filed financial statements (DART). TTM to H1 2026 revenue was ₩8.4B, operating income was -₩18.8B (margin -223.1%) and net income was -₩27.4B (margin -325.0%). Annual net losses were ₩13.6B (2021), ₩36.3B (2022), ₩12.7B (2023), ₩19.5B (2024) and ₩34.9B (2025). Revenue fell 72.9% in 2024 and 8.2% in 2025. ROE was -64.4% on a TTM basis and -110.4% in 2025. Liabilities to equity were 220.8%. Cash was ₩40.3B and TTM free cash flow was -₩20.7B, which on these two figures covers roughly two years of the current cash burn, though the data does not state a runway. Borrowings are not available in the data. A May 2026 filing relates to an early acquisition of convertible bonds before maturity, but the details are not in the data.

Valuation

With negative earnings, P/E and EV/EBITDA cannot be calculated. P/B is 48.3 (157 at the end of 2025) and P/S is 223.6. Peers in the data show P/B of 2.2 to 23.0 (Celltrion 2.2, Hanmi Pharm 4.3, Samsung Biologics 10.2, HLB 16.9, Alteogen 23.0), and those with earnings show P/E of 24.5 to 63.9, so Mezzion's P/B is well above all of them. The valuation model (5-year DCF, 6.1% rate, TTM to H1 2026) gives a base estimate of ₩669 per share, with a bear case of ₩818 and a bull case of ₩433. The bear case is higher than the base case, which is an oddity in the output. This is a model estimate based on the assumptions shown, not a target or a reason to buy or sell. All three values are far below the ₩62,900 share price, which implies the market is pricing in outcomes the model's cash flow assumptions do not capture.

Catalysts

• The half-year report for June 2026, filed 2026-08-14, is the latest set of financial statements and shows continued losses.
• Two 5%+ holding reports were filed on 2026-10-02 and 2026-10-08, indicating changes in major shareholdings, though the holders and direction are not in the data.
• Repeated insider shareholding reports between June and August 2026 show ongoing insider ownership changes, with details not available.
• The May 2026 filings on early acquisition of convertible bonds relate to the company's funding structure.
• No news headlines are available in the data, so no external events can be identified.

Risks

• Revenue has dropped from ₩31.7B in 2023 to ₩7.9B in 2025, and the TTM figure of ₩8.4B shows no clear recovery.
• Persistent operating losses and negative free cash flow of -₩20.7B against cash of ₩40.3B could require additional funding.
• Liabilities are 220.8% of equity, and borrowings data is not available to assess debt exposure.
• The P/B of 48.3 and P/S of 223.6 are far above peers, leaving the share price sensitive to changes in sentiment, as shown by a 52-week range of ₩45,850 to ₩179,900.
• Investor flow, foreign ownership and short balance data are not available, which limits visibility into who is driving trading.

Closing view

The filed numbers show a company with small and shrinking revenue, recurring losses and a market value far above both peer multiples and the model estimate. The data does not explain what the market is pricing in, and it lacks flow, news and pipeline information. Investors should weigh the large gap between the share price and the model estimate, and the cash position against the rate of cash burn, while recognizing the limits of this data.

Model estimate of fair value

Bear

₩818

-98%

Base

₩669

-99%

Bull

₩433

-99%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 6.1%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

• 5%+ holding reportOct 8, 2026
• 5%+ holding reportOct 2, 2026
• Half-year report (Jun 2026)Aug 14, 2026
• Insider shareholding reportAug 6, 2026
• Insider shareholding reportAug 6, 2026
• Insider shareholding reportAug 6, 2026
• Insider shareholding reportJul 28, 2026
• Insider shareholding reportJul 21, 2026
• Insider shareholding reportJul 14, 2026
• Insider shareholding reportJun 30, 2026
• 주요사항보고서(자기전환사채만기전취득결정)May 22, 2026
• 주요사항보고서(자기전환사채만기전취득결정)May 22, 2026
• Daily prices up to 2026-10-12
• Financial statements, trailing 12 months as of H1 2026
• Our fair value model, statements as of TTM to H1 2026

Report history

1. Oct 13, 2026InitiationStart of coverage (300 largest)Mezzion Pharma: Small Revenue, Continued Losses and a Market Value Far Above the Model Estimate